Matthew Pauls - Mar 28, 2025 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role
Director
Signature
/s/ Anish Bhatnagar, Attorney-in-Fact
Stock symbol
SLNO
Transactions as of
Mar 28, 2025
Transactions value $
-$397,487
Form type
4
Date filed
3/31/2025, 07:24 PM
Previous filing
Dec 16, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLNO Common Stock Options Exercise $27.3K +5.94K +91.34% $4.60 12.4K Mar 28, 2025 Direct F1
transaction SLNO Common Stock Sale -$425K -5.94K -47.74% $71.55 6.5K Mar 28, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLNO Employee stock option (right to buy) Options Exercise $0 -5.94K -39.58% $0.00 9.06K Mar 28, 2025 Common Stock 5.94K $46.31 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Certain of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F2 This transaction was executed in multiple trades at prices ranging from $71.54 to $71.69. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 One forty-eighth (1/48th) of the shares subject to the Option shall vest on September 15, 2023 and each month thereafter on the same day of the month, subject to the Reporting Person continuing to be a Service Provider through each such date.